NCT04022928

Brief Summary

Platelet-rich plasma (PRP) has been reported to be an effective treatment for knee osteoarthritis (OA). The application in ankle OA has rarely been investigated. The aim was to evaluate the efficacy and safety of a single intraarticular injection of PRP for the treatment of patients with ankle OA.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jul 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2018

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2018

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2019

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

July 11, 2019

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 17, 2019

Completed
Last Updated

July 19, 2019

Status Verified

July 1, 2019

Enrollment Period

5 months

First QC Date

July 11, 2019

Last Update Submit

July 17, 2019

Conditions

Keywords

Ankle jointOsteoarthritisPlatelet rich plasma

Outcome Measures

Primary Outcomes (1)

  • visual analog scale (VAS) of ankle pain

    The patient rated the average severity of ankle pain on ankle movement over the previous week on a 10-cm VAS (0=no pain to 10=worst possible pain)

    6 months

Secondary Outcomes (6)

  • The Ankle Osteoarthritis Scale (AOS) score

    6 months

  • The American Orthopedic Foot and Ankle Society (AOFAS) ankle/hindfoot score

    6 months

  • The single-leg stance (SLS) test

    6 months

  • use of analgesic medication

    through study completion, an average of 6 months

  • global satisfaction

    6 months

  • +1 more secondary outcomes

Study Arms (1)

PRP injection

EXPERIMENTAL

Patients with symptomatic ankle OA for at least 6 months were recruited. Patients received a single injection of 3-ml of PRP into symptomatic ankles.

Other: PRP

Interventions

PRPOTHER

, For PRP preparation, specialized platelet concentrate separator containing acid citrate dextrose as anticoagulant and a specific separator gel that harvest PR, preventing contamination of red blood cells and leukocytes were used.

PRP injection

Eligibility Criteria

Age20 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age of at least twenty years
  • Ankle pain lasted for at least 6 months, despite conservative treatment or inability to tolerate the side effects of medications
  • Ankle radiographs taken within 6 months (reviewed by the senior author) were equivalent to grade 1-4 osteoarthritis by the Kellgren Lawrence grading system
  • Average ankle pain of \> 3cm on a 10-cm visual analog scale (VAS)
  • Radiological evidence of bilateral ankle osteoarthritis was accepted if VAS pain in the contralateral ankle was \< 3 cm
  • Normal activity level, not bedridden or confined to a wheelchair, able to walk 30 meters without the aid of a walker, crutches or cane
  • No use of physical therapy or changes in shoes or orthotic devices during the study

You may not qualify if:

  • Pregnancy or lactation in women
  • Lower leg trauma in a location other than within the ankle
  • Previous surgery involving the spine, hip or knee
  • The presence of an active infection of the ankle
  • Surgery involving the affected ankle within the previous 12 months
  • Intraarticular steroid or hyaluronate injection in the ankle within the previous 6 months
  • Treatment with anticoagulants or immunosuppressives
  • History of rheumatoid arthritis, gout, or other inflammatory arthropathy
  • The presence of visual or vestibular impairments
  • Poor health status (such as a neoplasm, diabetes mellitus, or paresis) that would interfere with the assessments

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Physical Medicine and Rehabilitation, Veterans General Hospital Kaohsiung

Kaohsiung City, 813, Taiwan

Location

MeSH Terms

Conditions

Osteoarthritis

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Study Officials

  • Shu Fen Sun, MD

    Kaohsiung Veterans General Hospital, Taiwan

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: patients with symptomatic ankle OA for at least 6 months were recruited. Patients received a single injection of 3-ml of PRP into symptomatic ankles.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of Neutorehabilitation, MD,Department of Physical Medicine and Rehabilitation, Kaohsiung Veterans General Hospital

Study Record Dates

First Submitted

July 11, 2019

First Posted

July 17, 2019

Study Start

July 1, 2018

Primary Completion

November 30, 2018

Study Completion

May 30, 2019

Last Updated

July 19, 2019

Record last verified: 2019-07

Data Sharing

IPD Sharing
Will not share

Locations